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Cardiovascular disease is the most frequently occurring
major side-effect of steroid contraception. The World Health
Organization (WHO) report on cardiovascular disease and
steroid hormone contraception (WHO, 1998) gives us a well
documented state-of-the-art review of the evidence. The aim
of the independent Scientific Group convened by WHO was
'to review current scientific data on cardiovascular disease and
use of steroid contraception, to identify risk factors which
may predict, for individual women, an increased risk of
cardiovascular effects with use of different hormonal contra-
ceptives, and to assess whether the various compositions of
combined oral contraceptives have different risk profiles for
cardiovascular disease'.
Published and unpublished data were gathered, described and
discussed. Clinical, epidemiological and basic investigators,
various organizations in the field of cardiovascular disease
and steroid hormone contraception, major manufacturers of
hormonal contraceptives, äs well äs representatives of drug
regulatory authorities had the opportunity to communicate
with the Scientific Group. All participants had access to
background papers, unpublished data and the draft report. The
scientific background papers have been jointly published in
the March 1998 issue of Contraception. Three clinical cardio-
vascular entities were highlighted: acute myocardial infarction
(AMI), stroke, and venous thromboembolism (VTE).
Venous thromboembolism
Since venous thromboembolism has been the subject of major
attention recently (Benagiano, 1998; Cohen, 1998; Heimerhorst
et al, 1998; Kapar, 1998; Leader, 1998; Spitzer, 1998), we
will firstly consider the conclusions on this subject, and then
balance them with the conclusions regarding AMI and stroke.
Risk of VTE in combined oral contraceptive (COC) users
is 3-6 times that in non-users. After discontinuation, the risk
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diminishes quickly to that in non-users. This is no news so
far (Heimerhorst et al., 1997). Also the Scientific Group
accepts the gradually emerging data that risk is highest in the
first year of use. What is new, is their conclusion that the risk
of VTE is not related to the dose of oestrogen in preparations
containing <50 μg ethinyloestradiol. The Scientific Group
reconfirms the finding that COCs containing desogestrel (DSG)
or gestodene (GSD) 'probably carry a small risk of VTE
beyond that attributable to COCs containing levonorgestrel
(LNG)'. This conclusion rests upon the discussion of the
recently published and unpublished studies in the report, and
upon the scientific background paper by Walker (1998). DSG
and GSD are representatives of third generation progestins,
derivatives of the second generation progestin LNG. Second
generation progestins have been coupled with lower doses of
ethinyloestradiol (mostly 30 μg); all third generation progestins
are combined with =£30 μg ethinyloestradiol. The empirical
observation that the risk of VTE is not diminished further
when the dose of oestrogen in preparations is <50 μg
ethinyloestradiol might also be due in pari to the increased
risk of third generation progestins which are always combined
with lower'doses of ethinyloestradiol. Norgestimate (NGM) is
diffietrlt to classify because it is partially metabolized to LNG
and partially to other intermediates. Conclusions for NGM
cannot be drawn because of the insufficient availability of
data, which hopefully will be generated in the near future. The
absolute risk of VTE for women using COC is low but rises
with increasing age, with obesity, recent surgery and some
forms of thrombophilia (Factor V Leiden, protein C and
antithrombin deficiency).
Acute myocardial infarction
What we all know, but can hardly change, is the habit of
smoking, which is a major risk factor in arterial disease. Meirik
(1998a) concludes 'that for all women, regardless of age, the
risk of arterial cardiovascular disease attributable to smoking
is larger than that ascribable to COC use'. Women who use
COCs, who refrain from smoking, who have a normal blood
pressure, and who are not suffering from diabetes mellitus do
not have an increased risk of AMI, regardless of their age.
This conclusion by the Scientific Group is not new, but should
be emphasized again: selective prescribing might explain low
AMI frequency in countries with well developed health care
Systems where some form of screening for arterial risk factors
takes place before prescription. Duration and past COC use
are not related with an increased risk of AMI. The latter
observation points to an acute effect of COCs, which is
unlikely to be mediated by lipids. The claim that third
generation pills have a lower risk of AMI relative to second
generation preparations could not be substantiated on the basis
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of available studies. However, we must await for several
studies that are in the process of analysis. The studies may
support the relationship between the intermediate endpoints,
low density lipoproteins (LDL) and high density lipoproteins
(HOL) levels and, separately, a lower risk of AMI. In this
respect, the Scientific Group warns of misinterpretation when
comparisons of cases and controls are made between studies
rather than within the same study, äs differences in screening
and diagnostic procedures will be minimal within the same
study (see also Vandenbroucke et al., 1997).
Stroke
Risk of ischaemic (cerebral infarction caused by occlusion of
an artery or rarely a vein) or haemorrhagic (caused by an
arterial rupture) stroke associated with COC has decreased
during the history of COC. Still, a 1.5-fold risk of ischaemic
stroke is found in non-smoking, normotensive COC users
relative to non-users; and older women may have some elevated
risk of haemorrhagic stroke if they use COC. Duration of
use has no extra effect. Ethinyloestradiol dose is positively
correlated with ischaemic stroke. As soon äs use of the pill
has been discontinued, the risk disappears. Increased risk of
cerebral venous sinus thrombosis (a very rare condition) also
exists with COC, in particular in users of third-generation
formulations (de Bruijn et al, 1998).
Biological plausibility
Since the first case history of Jordan (1961) on the relation-
ship between COC and VTE, clinicians and scientists are
searching for biological understanding why COCs in some
women cause VTE. 'Integrated models of disrupted vascular
function' are now replacing conventional distinctions between
'atherogenesis' and 'thrombosis'. Hereditary defects in the
clotting System, which may underlie at least one-third of
idiopathic VTE in Caucasian women, may interact with steroid-
induced changes in lipid metabolism, haemostasis, vascular
wall and humoral regulators, e.g. insulin and the renin-
angiotensin system. According to the Scientific Group, there
is no reason to exclude a causal relationship or to minimize
the importance of epidemiological data, in the absence of
knowledge of the biological cause of cardiovascular disease.
This is especially true in the study of side-effects, in which it
is unlikely that a mechanism is presupposed äs the side-effect
is unexpected. Moreover, several interesting leads regarding
an acquired activated protein C-resistance (resulting in a
diminished anticlotting activity) mediated by COCs, might
offer the beginning of an explanation. The effect of COCs on
anticlotting activity in the blood has been found by different
researchers through the now classic lest for APC-resistance
(Heimerhorst et al., 1998).
number of women using COCs throughout the world means
that even modest elevations in risk have the potential to
affect a large number of women' (WHO, 1998). VTE is the
commonest cardiovascular event among COC users. Although
the incidence of mortality is low among the youngest group,
death due to VTE is relatively higher than due to AMI.
Considering the three cardiovascular diseases, the available
data and balancing pros and cons (Farley et al., 1998), the
Scientific Group speculates that mortality among older women
(>35 years) who smoke and use third generation preparations
is lower than in women using second generation COCs. For
healthy, first-time users, second generation COCs seem to
remain the first choice of prescription; and this advice can be
extended to all non-smoking women and to smoking women
aged <35 years. Since risk of cardiovascular disease among
COC users is increased by hypertension, the Scientific Group
sees the benefit of blood pressure measurement. Increased
attention to cardiovascular risk factors such äs hypertension
and smoking 'can achieve a greater reduction in cardiovascular
mortality than switching from second to third generation oral
contraceptives' (Farley et al., 1998).
Progestogen-only pills (POPs)
Unfortunately, available data to demonstrate a relation between
POPs and VTE, or between POP and stroke are insufficient.
Data from an unpublished WHO study found no increase in
risk of AMI among current POP users compared with non-users.
Criticism of the report
In a period of evidence based medicine, one may wonder
why the Scientific Group composed a narrative instead of a
systematic review. So far, systematic reviews are mainly based
on randomized controlled trials (RCT) for which quality control
by rather straightforward 'rule of thumb' exists. Although
progress can be seen in making guidelines for quality control
of non-randomized controlled trials, final judgement of obser-
vational research is a process in which several levels of
argument and counterargument should be integrated. Cardio-
vascular disease äs a side-effect of steroid contraception is
mainly investigated in a non-randomized fashion. 'The low
incidence of cardiovascular disease in women of reproductive
age has precluded the conducting of RCTs with clinical
endpoints' (Hannaford, 1998). We agree with Hannaford
(1998) that Observational cohort and case-control studies have
provided the most useful clinical Information about the main
cardiovascular effects of steroid contraceptives'. Other cri-
tiques (Spitzer, 1997) that were published before the report
was available (WHO, 1997) were rebutted by Meirik (1998b)
and Jick et al. (1998).
Balancing risks
The small increase in risk of cardiovascular disease must be
balanced against the very high contraceptive efficacy of COCs.
This obvious Statement does not stand alone. 'The very large
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Recommendations
More data on factors predisposing for cardiovascular diseases
among women using COC must be generated. Differences in
risk factors between developing and developed countries, e.g.
Venous thromboembolism and the pill
m screenmg for blood pressure may show us how steroids
mfluence the mcidence of cardiovascular disease
The major benefit of the recent third generation contraceptive
debate is an intensification of research on the remarkable
interaction between genetic and environmental factors which
cause and perhaps prevent cardiovascular diseases We have
gamed knowledge that will help all parties to develop even
safer contraceptives m the future
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